| Micromet AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120009204 | Treatment of Metastatic Breast Cancer - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody. | 01-12-2012 |
| 20120009195 | ANTIBODY NEUTRALIZERS OF HUMAN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR - The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF. | 01-12-2012 |
| 20110104172 | INHIBITORS OF GM-CSF AND IL-17 FOR THERAPY - The invention relates to a method for the treatment of an inflammatory disease in a subject suffering from the inflammatory disease, the method comprising the administration to said subject of a compound neutralizing GM-CSF; and a compound neutralizing IL-17. | 05-05-2011 |
| 20100183615 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 07-22-2010 |
| 20100150918 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN - The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (CD3 epsilon). | 06-17-2010 |
| 20090304716 | TREATMENT OF METASTATIC BREAST CANCER - The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody. | 12-10-2009 |
| 20090297532 | Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor - The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF. | 12-03-2009 |
| 20090241202 | DOMAIN-GRAFTED ANTIBODIES - The present invention relates to antibodies. Specifically, the present invention relates to antibodies composed of novel combinations of inter-species antibody domains (“domain-grafted antibodies”). The present invention further relates to compositions comprising such domain-grafted antibodies, as well as methods for producing such domain-grafted antibodies. Finally, the present invention relates to methods of evaluating the in vivo biological effect of such domain-grafted antibodies as well as uses of such domain-grafted antibodies for cross-species evaluation of the in vivo activity antibodies intended for human therapy. | 09-24-2009 |
| 20080317746 | Anti-Il2 Antibodies - The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interleukin-2 (IL2), wherein said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to said human IL2 prior to, during, and/or subsequent to the binding of said human IL2 to the human IL2-receptor, and wherein the light chain variable region of said humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46. | 12-25-2008 |
